Fierce Healthcare September 13, 2023
Pharmaceutical companies are waging war against federal agencies over one of the Inflation Reduction Act’s major provisions allowing Medicare to negotiate 10 drugs to reduce out-of-pocket costs for patients.
The highly anticipated list released in late August included popular blood clot prevention drugs Eliquis and Xarelto and diabetes drugs Jardiance and Januvia. It also included Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp.
These drugs are subject to a new drug negotiation standard, where the Centers for Medicare and Medicaid Services will send an initial price offer to companies by Feb. 1 based on months of listening sessions and submitted information provided by pharma companies that will include R&D and cost of production and distribution figures.
Drug...
Today's Sponsors
Today's Sponsor